$224.77
+1.88
(+0.84%)
As of Oct 7, 2026, 2:11 PM EDT
Price history
Today's analyst average
Analyst average over timeIndividual analyst targets
Analyst history starts Jul 31, 2026, the first target we tracked for BIIB.
Biogen (BIIB) is trading up at $224.77 (+0.84%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on BIIB
One firm's current price target on Biogen: $251 — 12% above the current $225. Each is tracked to its date and scored the same way a member's call is.
- H.C. Wainwright $203 → $251 by Jul 2027 Jul 31, 2026 via Investing.com · H.C. Wainwright's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Biogen revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $11.4B | $12.3B | $13.5B | $14.4B | $13.4B | $11.0B | $10.2B | $9.84B | $9.68B | $9.89B |
| Growth (year over year) | +6.4% | +7.2% | +9.6% | +6.9% | −6.5% | −18.3% | −7.4% | −3.3% | −1.6% | +2.2% |
| Gross profit | $9.97B | $10.6B | $11.6B | $12.4B | $11.6B | $8.87B | $7.90B | $7.30B | $7.37B | $7.49B |
| Gross margin | 87.1% | 86.7% | 86.5% | 86.4% | 86.6% | 80.8% | 77.6% | 74.2% | 76.1% | 75.7% |
| Operating income | $5.15B | $5.35B | $5.89B | $7.04B | $4.55B | $2.84B | — | — | — | — |
| Operating margin | 45.0% | 43.6% | 43.8% | 49.0% | 33.8% | 25.9% | — | — | — | — |
| Net income | $3.70B | $2.54B | $4.43B | $5.89B | $4.00B | $1.56B | $3.05B | $1.16B | $1.63B | $1.29B |
| Net margin | 32.3% | 20.7% | 32.9% | 41.0% | 29.8% | 14.2% | 29.9% | 11.8% | 16.9% | 13.1% |
| EPS (diluted) | $16.93 | $11.92 | $21.58 | $31.42 | $24.80 | $10.40 | $20.87 | $7.97 | $11.18 | $8.79 |
| Balance sheet | ||||||||||
| Cash and equivalents | $2.33B | $1.57B | $1.22B | $2.91B | $1.33B | $2.26B | $3.42B | $1.05B | $2.38B | $3.01B |
| Total assets | $22.9B | $23.7B | $25.3B | $27.2B | $24.6B | $23.9B | $24.6B | $26.8B | $28.0B | $29.4B |
| Total liabilities | $10.7B | $11.1B | $12.3B | $13.9B | $13.9B | $12.9B | $11.2B | $12.0B | $11.3B | $11.2B |
| Long-term debt | $16.4M | $0 | $5.94B | $4.46B | $7.43B | $6.27B | $6.28B | $6.79B | $4.55B | $6.29B |
| Shareholders' equity | $12.1B | $12.6B | $13.0B | $13.3B | $10.7B | $10.9B | $13.4B | $14.8B | $16.7B | $18.3B |
| Cash flow | ||||||||||
| Operating cash flow | $4.59B | $4.55B | $6.19B | $7.08B | $4.23B | $3.64B | $1.38B | $1.55B | $2.88B | $2.20B |
| Capital expenditure | $616.1M | $867.4M | $770.6M | $514.5M | $424.8M | $258.1M | $240.3M | $277.0M | $153.7M | $153.8M |
| Free cash flow | $3.97B | $3.68B | $5.42B | $6.56B | $3.81B | $3.38B | $1.14B | $1.27B | $2.72B | $2.05B |
| Share buybacks | $1.00B | $1.37B | $4.35B | $5.87B | $6.68B | $1.80B | $750.0M | $0 | $0 | — |
RevenueNet income
| Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.46B | $2.47B | $2.45B | $2.43B | $2.65B | $2.53B | $2.28B | $2.48B |
| Growth (year over year) | +0.4% | −2.5% | +2.9% | +6.1% | +7.3% | +2.8% | −7.1% | +1.9% |
| Gross profit | $1.92B | $1.83B | $1.87B | $1.80B | $2.04B | $1.86B | $1.78B | $1.82B |
| Gross margin | 77.8% | 74.1% | 76.2% | 74.1% | 77.1% | 73.4% | 78.3% | 73.3% |
| Net income | $583.6M | $388.5M | $266.7M | $240.5M | $634.8M | $466.5M | −$48.9M | $319.5M |
| Net margin | 23.7% | 15.8% | 10.9% | 9.9% | 24.0% | 18.4% | −2.1% | 12.9% |
| EPS (diluted) | $4.00 | $2.66 | $1.82 | $1.64 | $4.33 | $3.17 | −$0.35 | $2.15 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.91B | $1.70B | $2.38B | $2.60B | $2.76B | $3.86B | $3.01B | $3.38B |
| Total assets | $26.8B | $28.3B | $28.0B | $28.0B | $28.3B | $29.2B | $29.4B | $29.5B |
| Total liabilities | $10.9B | $12.0B | $11.3B | $11.1B | $10.7B | $11.0B | $11.2B | $10.8B |
| Long-term debt | $6.29B | $4.55B | $4.55B | $4.55B | $6.28B | $6.29B | $6.29B | $6.29B |
| Shareholders' equity | $15.9B | $16.4B | $16.7B | $17.0B | $17.6B | $18.2B | $18.3B | $18.7B |
| Cash flow | ||||||||
| Operating cash flow | $625.8M | $935.6M | $760.9M | $259.3M | $160.9M | $1.27B | $511.9M | $645.5M |
| Capital expenditure | $33.5M | $35.0M | $39.3M | $37.1M | $26.6M | $46.2M | $43.9M | $51.2M |
| Free cash flow | $592.3M | $900.6M | $721.6M | $222.2M | $134.3M | $1.23B | $468.0M | $594.3M |
From Biogen's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Biogen
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
- Headquarters
- Cambridge, Massachusetts From SEC filings, Oct 2026
Recent News (20)
-
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy
-
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab i…
-
Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva With 190 live customers and 14 top 20 biopharma commitments, Vault CRM is the fastest path to AI PLEASANTON, Calif., Sept. 23, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new top…
-
Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva With 190 live customers and 14 top 20 biopharma commitments, Vault CRM is the fastest path to AI PLEASANTON, Calif., Sept. 23, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new top…
-
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT stu…
-
Is Biogen Stock Outperforming the S&P 500?
Is Biogen Stock Outperforming the S&P 500?
-
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside? Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside? Yahoo Finance
-
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?
-
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology
-
-
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet
-
-
-
-
-
Biogen Completes Acquisition of RayThera Inc. Lead program now in Phase 1 development Lead program now in Phase 1 development
-
-
-
Why Biogen Stock Topped the Market Today Why Biogen Stock Topped the Market Today
-
Biogen Inc. Q2 2026 Earnings Call Summary Biogen Inc. Q2 2026 Earnings Call Summary
More Health Care stocks
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International
- BDX Becton Dickinson
- BMY Bristol Myers Squibb
- BSX Boston Scientific
- CAH Cardinal Health
- CI Cigna